98%
921
2 minutes
20
Sonodynamic therapy (SDT) is a non-invasive alternative treatment for cancer. However, its effects on early-stage and intradermally implanted melanoma remain underexplored. Here, we investigated the in vivo effects of 5-aminolevulinic acid (ALA)-mediated SDT on early-stage murine cutaneous melanoma. Three comparative analyses were conducted to evaluate: (1) the efficacy of SDT on tumors at two distinct stages-Stage 1 and Stage 2-defined in this study based on Breslow depth: 1-1.5 mm for Stage 1 and 2.5-3 mm for Stage 2; (2) the therapeutic potential of combining SDT with photodynamic therapy (PDT) in Stage 1 tumors; and (3) the effectiveness of two ultrasound delivery approaches-via waveguide and direct contact. SDT induced significant tumor growth inhibition in Stage 1 (86.5%) and Stage 2 (72.5%) tumors compared to controls. The combination of SDT and PDT did not result in significantly greater tumor growth inhibition compared to SDT or PDT alone in Stage 1 tumors. ALA-mediated SDT thus demonstrates potential as a therapeutic strategy for early-stage cutaneous melanoma. However, under the conditions employed, combining SDT with PDT did not enhance therapeutic efficacy. Both waveguide-mediated and direct-contact ultrasound delivery proved effective for treating Stage 2 tumors, with waveguides offering advantages in anatomically challenging regions.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12373959 | PMC |
http://dx.doi.org/10.1038/s41598-025-16366-x | DOI Listing |
Foot Ankle Int
September 2025
Department of Orthopaedic Surgery, St. Luke's University Health Network, Bethlehem, PA, USA.
Background: In response to the opioid epidemic, many surgical specialties have adopted nonopioid pain management strategies. Ultrasound (US)-guided peripheral nerve blocks (PNBs) are effective in reducing pain and opioid consumption postsurgery. Liposomal bupivacaine (LB), shown effective in shoulder surgery, was approved in November 2023 for use in US-guided lower extremity blocks.
View Article and Find Full Text PDFNeuro Oncol
September 2025
Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Background: Disruption of the blood-brain barrier (BBB) in high-grade brain tumors is characterized by contrast accumulation on diagnostic imaging. This window of opportunity study correlates contrast imaging features with the tumor distribution of BBB-permeable (levetiracetam) and -impermeable (cefazolin) drugs.
Methods: Patients with a clinical diagnosis of a high-grade brain tumor underwent MRI for surgical planning.
ACS Chem Neurosci
September 2025
Institute of Cell Engineering, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21215, United States.
Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive impairment and neuronal loss, with pathological hallmarks including Aβ plaque deposition and tau tangles. At present, the early diagnosis and treatment of AD still face great challenges, such as limited diagnostic methods, difficulty in blood-brain barrier (BBB) penetration, complex disease mechanisms, and lack of highly effective targeted therapies. Antibody drugs have shown broad prospects in the field of AD due to their high specificity, engineering and multifunctional therapeutic potential, include targeted Aβ clearance, tau pathological regulation, imaging probes, and blood biomarkers.
View Article and Find Full Text PDFBiomaterials
September 2025
Institute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, 610041, PR China. Electronic address:
Host immune elimination largely limits the application of oncolytic viruses in clinics. Here, we rationally design a bioactive platelet-based oncolytic adenovirus delivery system. Upon loading adenoviruses, platelets are transformed to a pro-endocytosis status, which facilitates their internalization by circulating tumor cells (CTCs).
View Article and Find Full Text PDFAnal Chim Acta
November 2025
Institute of Materials Science, Vietnam Academy of Science and Technology, Hanoi, 10000, Viet Nam. Electronic address:
Background: Recent advancements in cancer therapeutics have catalyzed the development of noninvasive treatment modalities, including the utilization of fluorescent chemotherapeutic agents. These agents offer dual functionality, enabling targeted drug delivery, real-time tumor imaging, and personalized therapy monitoring. Such capabilities are instrumental in the progression toward more precise and effective cancer interventions.
View Article and Find Full Text PDF